Halozyme Therapeutics, Inc. (HALO): Long-Term Debt
$2.14B
As of 2025-12-31
+12.5%
3-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.14B | +42.3% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $1.51B | +0.4% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $1.50B | -0.5% | 2025-02-18, Balance as of period end |
| 2022-12-31 | $1.51B | +91.3% | 2024-02-20, Balance as of period end |
| 2021-12-31 | $787.25M | n/a | 2023-02-21, Balance as of period end |
| 2020-12-31 | $0 | -100.0% | 2022-02-22, Balance as of period end |
| 2019-12-31 | $383.05M | +998.4% | 2021-02-23, Balance as of period end |
| 2018-12-31 | $34.87M | -72.1% | 2020-02-24, Balance as of period end |
| 2017-12-31 | $125.14M | -37.2% | 2019-02-21, Balance as of period end |
| 2016-12-31 | $199.23M | +612.3% | 2018-02-20, Balance as of period end |
| 2015-12-31 | $27.97M | -43.9% | 2017-02-28, Balance as of period end |
| 2014-12-31 | $49.86M | +0.2% | 2016-02-29, Balance as of period end |
| 2013-12-31 | $49.77M | +67.8% | 2015-03-02, Balance as of period end |
| 2012-12-31 | $29.66M | n/a | 2014-02-28, Balance as of period end |
| 2011-12-31 | $0 | n/a | 2013-03-01, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.14B | +42.3% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $1.65B | +18.9% |
| Repligen Corp (RGEN) | 2025-12-31 | $542.21M | +3.2% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $72.14M | -0.3% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $72.44M | +0.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $6.29B | -0.1% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $54.28M | n/a |
| Agenus Inc (AGEN) | 2025-12-31 | $44.66M | +34.6% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $24.94B | -6.6% |
Compare HALO, QGEN, RGEN, ADMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗